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1. Introduction 
Penile cancer is a malignant neoplasm found on the skin or in the tissues of the penis. More 
than 95% of malignant tumours are carcinomas, and squamous cell carcinoma accounts for 
most cases of penile malignancies. The other rare neoplasms include malignant melanoma, 
sarcoma, Paget’s disease, lymphomas and metastases from other sources as well as the 
urothelial carcinoma of the urethra can involve the penis by local spread [1]. 
 
1.1. Carcinoma of the penis 
Penile squamous cell carcinoma (PSCC) is an uncommon tumour. PSCC almost arises in the 
epithelium of the foreskin, coronal sulcus and glans. The behaviour of PSCC is more or less 
like squamous cell carcinoma (SCC) of the oropharynx, uterine cervix, vagina, vulva and 
anus. Nowadays, there is more information about of the natural history of the disease, earlier 
diagnosis, better technology, research group collaboration and centralisation of patients in 
centres of excellence. These factors lead to improvement the cure rate for penile cancer from 
50% in the 1990s to 80% in 2008 [2].  
 
1.1.1. Epidemiology and geographic distribution patterns 
The carcinoma of the penis accounts for 0.4% of all cancers in the male population and 2–4% 
of all genitourinary malignancies in developed countries [3]. There is a wide geographic 
distribution, with low frequency in Western world and higher frequencies in Africa, Latin 
America, and Asia. In developed countries, primary PSCC is rare, with an incidence of less 
than 1 per 100,000 males in Europe and the United States of America (USA) [4,5]. In 
developing countries, by contrast, the incidence rate of primary PSCC is much higher and can 
make up 10-20% of malignant disease in men ranging from middle to old age. Despite these 
statistics, the incidence of penile carcinoma has been declining in many countries, partly 
because of increased attention to personal hygiene. Although blacks are more commonly 
diagnosed than whites with a ratio of 2:1, racial predilection has not been clearly proven and 
any observed racial differences are more likely due to socioeconomic or environmental 
factors. PSCC most commonly occurs in the sixth decade of life, but may occur in men 
younger than 40 years. Such cases have been reported in Whites, Asians, Jews, Arabs, Native 
Indians of South America, and Afro-Americans. There is no racial preference for penile 
carcinomas. Familial cases also have been noted [6]. 
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1.1.2. Etiology 
Carcinoma of the penis has been strongly associated with phimosis and poor local hygiene. 
Phimosis is found in more than half of the patients in most series of penile carcinoma. The 
irritative effect of smegma, a by-product of bacterial action on desquamated epithelial cells 
within the preputial sac, is well known, although definitive evidence of its carcinogenic role is 
lacking. Neonatal circumcision as practiced by groups such as the Muslim and Jewish 
populations virtually eliminates the occurrence of penile carcinoma. Postponement of 
circumcision until puberty does not have the same benefit as neonatal circumcision, and adult 
circumcision dose not provide any protection against carcinoma of the penis [7]. Among 
patients with condylomata acuminata the risk of carcinoma is increased for vulva, vagina, 
penis and anus [6]. Human papillomavirus (HPV) infection, particularly HPV-16, has been 
implicated in the development of invasive penile carcinoma, as has the number of sexual 
partners [8]. HPV-16 and -18 have a causal role in 70% of carcinomas of the cervix, the 
vagina and the anus and about 30-40% of carcinomas of the vulva, penis and oropharynx. 
Other cofactors are very likely to be necessary for progression from HPV infection to cancer. 
High-risk types of HPV, including 16, 18, 31, 33, 39, 45, 52, 58, and 59, have been linked to 
cervical, vulvar, penile, and a smaller percentage of oropharyngeal carcinomas [8]. Five years 
ago, a vaccine against HPV was recommended for immunization of females and males in the 
USA. Surprisingly, the presence of high-risk HPV DNA in penile carcinoma does not 
compromise the prognosis; instead, more recent studies suggest that the presence of high-risk 
HPV confers a survival advantage in patients with penile carcinoma. The consumption of 
tobacco products has been shown to be an independent risk factor in the development of 
penile carcinoma on multivariate analysis. Tobacco has been proposed as a promoter of 
malignant transformation in the setting of infection and chronic irritation. Thus, avoidance of 
tobacco products and HPV infection, penile hygiene and neonatal circumcision represent 
important preventive strategies against penile carcinoma [6].  
 
1.1.3. Signs and symptoms 
Carcinoma of the penis usually begins with a small lesion that gradually extends to involve 
the entire glans, shaft, and corpora. The symptoms range from a relatively subtle induration or 
small excrescence to a small papule, pustule, warty growth, or a more luxuriant exophytic 
lesion. It may appear as shallow erosion or as a deeply excavated ulcer with elevated or 
rolled-in edges. Phimosis may obscure a lesion, allowing a tumour to progress silently. Foul 
preputial odour and discharges with or without bleeding call attention to the disease. Penile 
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carcinoma may present anywhere on the penis, but it occurs most commonly on the glans 
(48%), the prepuce (21%), or in both locations (9%), and along the coronal sulcus (6%).  
Rarely a mass, ulceration, suppuration or hemorrhage in the inguinal area may be due to nodal 
metastasis from a lesion concealed within a phimotic foreskin. Urinary retention or urethral 
fistulas due to local corporal involvement are rarely presenting symptoms. Pain does not 
develop in proportion to the extent of local destructive process and usually is not a presenting 
complaint. Weakness, weight loss, fatigue, and systemic malaise are secondary to chronic 
suppuration. On occasion, significant blood loss from the penile lesion, the nodal lesion, or 
both may occur. As local disease and regional disease are usually far advanced by the time 
distant metastasis occurs, the symptoms belonging to such metastasis are rare [6-9]. 
 
1.1.4. Pathology 
SCC accounts for more than 95% of all malignant primary neoplasms of the penis with 
multiple histological variants. The usual type accounts for 70% of PSCC [1]. Other 
histological variants represent up to 25%. These include verrucous SCC, warty SCC, basaloid 
SCC, sarcomatous SCC, papillary SCC, adenosquamous carcinoma, and mixed carcinomas. 
Other malignant epithelial tumours of the penis are Merkel cell carcinoma, small cell 
carcinoma of endocrine type, sebaceous cell carcinoma, clear cell carcinoma, and basal cell 
carcinoma. It is not known how often SCC is preceded by premalignant lesions. Such 
premalignant lesions include lesions that are sporadically associated with SCC of the penis, 
e.g. cutaneous horn of the penis, Bowenoid papulosis of the penis, and balanitis xerotica 
obliterans (lichen sclerosus et atrophicus). Other lesions that lead to a high risk of developing 
SCC of the penis are erythroplasia of Queyrat (carcinoma in situ of the glans) and Bowen’s 
disease (carcinoma in situ of the shaft). Further neoplasia of the penis includes melanocytic 
tumours, mesenchymal tumours, hematopoietic tumours, and secondary tumours [10].   
 
1.1.5. Clinical assessment, staging and treatment of lymph node metastases   
The therapeutic approach to clinically normal inguinal lymph nodes remains one of the 
biggest controversies in the treatment of invasive penile carcinomas, as 20-25% of all patients 
with clinically normal inguinal lymph nodes have occult metastases [11]. Patients with 
enlarged lymph nodes in the groin constitute 30-60% of all PSCC [12]. In about half of these 
patients, this is caused by metastatic invasion and in the other half by inflammatory reactions 
[13]. Treatment strategies are hampered by inaccuracies in the physical examination and 
imaging modalities, which makes it difficult to reliably identify the presence or absence of 
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lymph node metastases. Accurate histological diagnosis and staging of both the primary 
tumour and the regional nodes are necessary for making treatment decisions [14]. The lymph 
node status can be divided into the following types: 
 
1.1.5.1. Unsuspicious inguinal lymph nodes and their management 
When the inguinal lymph nodes are not palpable, an ultrasound of both inguinal regions may 
show abnormal nodes and can be used as a guide for fine-needle aspiration cytology or 
punction biopsy [15]. A sentinel lymph node biopsy (SLNB) [16] can not be recommended as 
standard procedure due to a high rate of false-negative results (25% range 9-50%) [17]. 
However, the performance of dynamic SLNB compared to a ‘wait-and-see’ policy was shown 
to be associated with improved survival and in a prospective study had 100% specificity and 
95% sensitivity [18]. Because of the high delicacy as well as complexity of dynamic SLNB, 
the procedure is only available in few centres. Conventional computer tomography (CT) or 
magnetic resonance imaging (MRI) cannot detect micrometastases [19]. Large studies are 
required to confirm the good results reported using nanoparticle-enhanced MRI and positron 
emission tomography (PET/CT) imaging [20]. Lymphadenectomy (LAD) is mandatory for 
patients with inguinal lymph node metastases. LAD is often followed by prolonged lymph 
leakage, which can result in leg and scrotal lymphoedema (2-100%), wound infection (10-
20%), skin necrosis with or without wound dehiscence (14-65%), lymphocele/seroma (19-
45%), and other complications like haemorrhage and thrombosis as well as inguinal hernia 
[21]. These complications had been reported in 30-70% of patients. Because of this high 
morbidity, inguinal lymphadenectomy should be performed in centres of experience with this 
procedure (meticulous lymph node dissection) as well as the postoperative care of the patients 
(careful skin flap management, prophylactic antibiotics, compressive stoking and early 
ambulation). Nodal metastases were found in 100% of pT3-T4, in 82% of pT2 tumors in 
around 218 patients with PSCC [22]. Metastasis within T1 tumors were seen mainly in 
moderate to high grade tumors, with 60 % in T1G2-3 and only 16.5% in low grade T1 tumors 
[22]. Patients with T1G2 are recommended to undergo surgical LN staging even in the face of 
clinically negative groins and the absence of lymph node invasion [23]. Patients with pT3-T4 
and all G3 are unequivocal candidates for bilateral LAD. Others reported lymph node 
metastases in 12% of pT1G2 [24], a category that is defined as ‘intermediate risk’ according 
to the EAU guidelines [2]. Dynamic SLNB appears to be very promising [25]. The acceptance 
of dynamic SLNB relies on the assumption that there is a stepwise progression of the primary 
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lymph node (sentinel lymph node) to secondary lymph nodes. There may be multiple sentinel 
lymph nodes [26].  
 
1.1.5.2. Palpable inguinal lymph nodes and their management 
When the inguinal lymph nodes are palpable, this would be due to either inflammatory 
reactions or lymph node metastasis. Up to 50% of palpable inguinal nodes are due to reactive 
inflammatory reactions rather than due to lymph node metastasis. This justifies the use of 
antibiotics for a period of 4-6 weeks to let a chance for these lymph nodes to subside. Then 
regional nodes should be re-evaluated within few weeks. On the contrary, nearly all enlarged 
lymph nodes noticed during the follow up are metastatic [12]. An assessment of distant 
metastases (pelvic or abdominal CT) should be restricted to patients with proven positive 
inguinal nodes. Although this is not a very reliable diagnostic method for the detection of 
micrometastasis, the detection of pelvic masses has a considerable impact on therapy and 
prognosis [24].  
The enlarged and not fixed palpable inguinal lymph nodes don’t necessarily signify metastatic 
disease. False-positive nodes has been reported to be as high as 50% [12,22]. Fine-needle 
aspiration cytology provides an excellent and rapid method to detect metastatic involvement 
in these patients. As dynamic SLNB is not reliable in enlarged lymph nodes [25], a repeat-
fine-needle aspiration cytology in suspected cases with tumour-negative findings is 
recommended. Consequently, early LAD (uni- or bilateral) should be performed in all 
tumour-positive patients [26]. In contralateral non-palpable lymph nodes, surgical staging is 
recommended. 
 
1.1.5.3. The pelvic lymph nodes and their management 
There is no direct lymphatic drainage from the primary tumour to the pelvic lymph nodes 
[27], and the term skip lesions refers to the presence of metastasis without any evidence of 
inguinal lymph node involvement are very rare and should be seen as a result of 
haematogenous metastasis. Pelvic lymph node dissection is only indicated in the presence of 
two or more inguinal nodes involvement or extranodal growth. Only the number of positive 
inguinal lymph node as well as extracapsular extension is regarded as the main pathological 
predictors for the potential involvement of pelvic nodes [28]. Pelvic LAD can be performed as 
a secondary procedure and through a midline suprapubic extraperitoneal incision. Positive 
pelvic nodes were reported as high as 23% and 56% in patients with two and more than two 
positive inguinal nodes respectively [29].  
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Variable studies show a significant relation between angiogenesis as a prognostic factor in 
SCC of different organs, such as uterine cervix, oral cavity, oesophagus, larynx, and lung. 
 
1.2. Angiogenesis  
Angiogenesis is the formation of new blood vessels from the endothelium of the existing 
vasculature and is the result of a complex multistep process involving extracellularmatrix 
remodeling, endothelial cell migration and proliferation, loop formation, capillary 
differentiation, anastomosis, and finally lumen development [30]. Vasculogenesis is the 
embryonic establishment of blood supply from mesodermal precursors such as angioblasts or 
hemangioblasts. Tumour angiogenesis refers to a combination of angiogenesis and 
vasculogenesis in which the main blood supply to a tumour derives from preexisting blood 
vessels, but circulating endothelial cell precursors may contribute to the growing vascular tree 
as well [31].  
Angiogenesis is an essential process involved in the normal growth and neoplasm 
differentiation [30]. In its defective and excessive form, angiogenesis is a crucial event in the 
progression of many human diseases. Excessive angiogenesis was largely investigated in 
psoriasis, arthritis, diabetic retinopathy and malignant tumours. Soon after the discovery of 
angiogenic factors and their inhibitors, angiogenesis investigation jumped from experimental 
studies to clinical application. Tumour-associated angiogenesis is nowadays considered as a 
priority in oncology, based on numerous evidences that show a significant reduction in 
tumour growth following anti-angiogenic therapy. 
It is now generally accepted that tumour angiogenesis is crucial both for the growth of a 
primary neoplastic tumour and also for the development of metastasis [30]. Several studies 
suggest that tumour angiogenesis is associated with tumour progression and outcome in a 
number of malignancies [32-34]. Although it is difficult to measure angiogenesis directly in 
human tumours, it is suggested that a quantification of immunohistochemically stained 
microvessels in histological sections, microvessel density (MVD) may be used as an index 
[32]. As the interest for the use of angiogenic inhibitors in cancer therapy increases rapidly, it 
is necessary to have valid conclusions for the importance of microvessel counts and VEGF 
expression in order to address their impact on the prognosis and their use as surrogates [35]. 
The most common antibodies used for microvessel staining so far are “anti von Willbrand 
Factor” (Factor VIII) antibodies, CD31, CD34, and recently CD105 [36,37].  
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CD34 is a single-chain transmembrane glycoprotein of approximately 116 kDa. CD34 is 
expressed on immature haematopoietic stem/progenitor cells, capillary endothelial cells, 
embryonic fibroblasts and rare glial cells in nervous tissue [38]. CD34 appears to be 
expressed at its highest level on the earliest progenitors, and seems to decrease progressively 
with maturation [39]. CD34 is a stage-specific, rather than a lineage-specific, leukocyte 
differentiation antigen. Monoclonal antibodies to CD34 can be confined to three main classes 
class I, class II and class III, defined by the differential sensitivity of the corresponding CD34 
epitopes to degradation by specific enzymes. The QBEnd 10 antibody is a class II monoclonal 
antibody that recognizes a CD34 epitope that is resistant to neuraminidase, and sensitive to 
glycoprotease and chymopapain. Anti-CD34 antibody is a highly sensitive marker for 
endothelial cell differentiation, which stains neoplastic endothelium a deeper shade than 
normal endothelium [40].  
 In this study, CD34 was selected as a marker for evaluating angiogenesis in PSCC because a 
CD34 is a more specific marker for neoformed vessels than other markers such as Factor VIII 
and according to some authors, a positive relationship of microvessel density and prognosis 
was reported in prostate adenocarcinoma for the endothelial marker CD34, but not for the 
CD31 [41].  
 
1.3. Objectives of the study 
 
1. To study the biological features of PSCC using MVD and to assess the role of MVD 
in the possibility of predicting lymph node metastasis in the primary tumour. 
2. To assess the role of MVD in predicting the prognosis and survival of patients with 
PSCC. 
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2. Materials and methods 
2.1. Materials 
2.1.1. Tissue samples 
The material studied comprised of formalin-fixed, paraffin-embedded (FFPE) tissue samples 
from a total of 89 patients with histologically confirmed squamous cell carcinoma of the 
penis, from the Departments of Urology in of the University Hospitals in Kiel, Giessen, 
Marburg, and Mannheim (all Germany), collected between 1996 and 2005. The tissue 
samples vary from one to three sections per patient.  
 
2.1.2. Characteristics of Patients  
The inclusion criteria of the patients with PSCC included invasive tumours, initial treatment 
of the primary tumour in one of our study centres, known clinical groin status at first 
presentation (established by clinical examination and/or computer tomography /ultrasound), 
and a postoperative nodal status proved by lymph node dissection or uneventful follow-up of 
24 months or more. The total number of patients who met the inclusion criteria was 64 cases. 
Three patients were excluded because of technical limitations of the staining, either weak 
staining intensity, or excessive background staining of the slides. The median age of the 
patients was 65 (39-84) years, and the follow-up after treatment was 32 (1-126) months.  
During the follow up period, 19 patients died (16 and 3 because of the tumour burden and 
other reasons, respectively). The tumours were evaluated according to the TNM and WHO 
classification system of 2002 and 2004, respectively [10,42]. The tumours were staged as T1 
in 22 patients, T2 in 31, T3 in 7 and T4 in 1 patient. The grading was well in 12, moderate in 
26 and poorly differentiated in 23 patients. The lymph node status was negative (N0) in 31 
patients (N1) metastasis in a single inguinal lymph node in 12 patients, (N2) metastasis in 
multiple or bilateral inguinal lymph nodes in 12 patients, and (N3) extranodal extension of 
lymph node metastasis or pelvic lymph node(s) unilateral or bilateral in 6 patients. Table (1) 
summarises the clinicopathological data of these patients. 
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Age 39-84 y 
 
T Stage 
 
 
T1  
 
22 
T2  
 
31 
T3  
 
7 
T4  
 
1 
Grade 
 
 
G1 12 
 
G2 26 
 
G3 23 
 
N Stage 
 
 
N0  
 
31 
N1  
 
12 
N2  
 
12 
N3  
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Table1. Patients and clinicopathological parameters (n = 61). 
2.2. Methods  
2.2.1. Immunohistochemical staining 
All tumour tissues were fixed in 10% neutral buffered formalin and processed for paraffin 
sectioning, which represents 3 micrometer paraffin sections. Normally, formalin fixation 
produces methylene cross-links between nucleic acids and/or proteins. This induces cross-
links that may mask some epitopes, resulting in a loss of immunoreactivity. In order to 
prevent this process, the “unmasking” of some epitopes from Formalin-Fixed Paraffin-
Embedded tissue is accomplished by antigen retrieval techniques. This is achieved by heat 
treatment (heat-induced antigen retrieval), which is the most commonly used approach to 
optimize antigen detection. 
 
 10 
In this study immunohistochemistry was carried out using monoclonal mouse antihuman 
CD34 class II, code no.M7165, at a dilution of 1:50 (DAKO, Glostrup, Denmark). The ready-
to-use CD34 Class II, Clone QBEnd 10, is intended for use in immunohistochemistry together 
with Autostainer Link instruments.  
The paraffin sections were dried in a slide incubator (Medite GmbH, Germany) at 37°C over 
night. Figure 1. 
 
Figure 1: Slide incubator (Medite GmbH, Burgdorf, Germany). 
The deparaffinization and epitope demaskation were made in a target retrieval solution (pH 
6.1) in the PT-module link (DAKO, Denmark) at 95° C over 25 min. Figure 2.  
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Figure 2: Pre-treatment Tanks module, PT Link, DAKO, Denmark. 
After that, the slides were cooled down to 65°C in the PT-module, taken out into the wash 
buffer and then cooled down again to room temperature. Afterwards, the slides were put into 
the Autostainer Link 48 (Autostainer Link 48, Fremont, Denmark) and were left to be stained 
automatically. Figure 3.  
In this study, the immunohistochemical treatment was done by the streptavidin-biotin method. 
The detection principle by this method of streptavidin-biotin conjugation was as follows: 
A biotinylated secondary antibody was used to recognize the primary antibody; streptavidin 
complexed with biotinylated peroxidase was then bound to the secondary antibody 
(streptavidin has an extremely high affinity to biotin). These reactions deliver several 
peroxidase molecules to the primary antibody binding site and so boost the sensitivity.  
The primary antibody was put on for 30 min, and washed afterwards with wash buffer. The 
masked secondary antibody was then incubated for 15 min with biotin and rinsing steps were 
done with wash buffer. Then streptavidin alkaline phosphatase was added for 20 min. The 
slides were again and carefully rinsed with the chromogen, which was the colour-producing 
reactant in the detection system. This method was applied here by using 3-amino-9-ethyl 
carbazole (AEC, which produces a red colour). Chromogen was applied for 10 minutes to 
form a biotin-streptavidin complex and was rinsed off with distilled water. A counterstaining 
by Haematoxylin was done for 2 min to represent the cell nuclei optimally. Bluing was then 
achieved by rinsing the slides under the tap water for 5 min. Lastly, the water was rinsed by 
99.9% alcohol, and the slides were prepared for mounting with a cover slip and resinous 
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medium by removal of the alcohol by using xylene rinses. The tonsillar tissue was used as a 
positive control, in which the antibody labels endothelial cells. The negative control was the 
section of the patient’s tissue, in which the antibody was not added and was replaced by non-
immune serum. Both positive and negative controls were run simultaneously with the patient 
specimen.  
 
Figure 3: Autostainer Link 48, DAKO, Fermont, Denmark: Automated immunostaining 
devices can improve standardization and reproducibility of immunohistochemical procedures.  
2.2.2. Microvessel density (MVD) assessment 
2.2.2.1. Light microscope 
The sections were examined for inflammation and vascular invasion under a light microscope 
(Axioskop Zeiss-Germany 350x233-18kg jpg Nikon). The immunohistochemical positive 
reaction of CD34 antibodies was counted, considering its expression in the cytoplasm of 
endothelial cells which lined the blood vessels.  
2.2.2.2. Automated Cellular Imaging System 
For the counting of microvessel density (MVD), the slides were scanned in DAKO, ACIS® 
Automated Cellular Imaging System with System software: ACIS® version 3.0.1 Operating 
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system: Microsoft Windows XP Professional. Figure 4. This was achieved through three main 
steps:  
2.2.2.2.1. Calibration 
Calibration was performed by using four calibration slides; a grid slide for focus and white 
balance, a chrome slide for black balance and tow ladder slides for linearity. One-touch 
calibration of the computer with the microscope platform was tested and passed successfully 
in all magnification levels.  
2.2.2.2.2. Slide identification 
Each slide was given a special code number. This was established through labelling of the 
slides by slide number and code number, which were printed with a check mark in order to 
enable the computer system to recognise it later. The application MVD Histo-Red Protocol 
was selected. Every four slides were put on a slide carrier, then into the slide hopper of the 
microscope, and running of the slides was ordered.  
2.2.2.2.3. Vessel count  
The counting was performed according to Weidners method [64]. All slides were captured 
using a RGB Digital camera and digitilizer and were transformed into pixels. Then they were 
analyzed using a combination of RGB and HSI colour spaces. The colour space 
transformation has three components: 1. “Hue” of colour means red versus blue. 2. 
“Saturation” means the purity of the colour, e.g. pink is desaturated red. 3. “Luminosity” 
means the brightness or intensity of the colour. This allowed for objective scoring, 
quantification, sensitive and rapid rare event detection and permitted the identification of 
hotspots. 
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Figure 4: Automated Cellular Imaging System (ACIS 3) version 3.0.1 Operating system, 
DAKO, Denmark.  
The sequences of the operation included four phases of analysis 1. Find: using a 4x objective, 
the entire scannable area was searched for stained specimen. 2. Focus: multiple points could 
be used to establish autofocus. 3. Scan: a flat approximation to the specimen surface was 
derived from these sampled points. 4. Collection: this approximation allowed for quantity 
imaging during scanning and faster refocussing during collection. 
The imaging system created histological reconstruction. The image of the entire tissue section 
was composed of hundreds or thousands of individual microscope fields. After selection of 
the hotspots regions for scoring, the image system immediately quantified the level of staining 
intensity and converted the intensity to a score, so as to achieve accurate data on the 
individual regions and multiple region statistics. 
Scanning of the slides and hotspots at a low resolution of magnification was done by using 
colour to detect positive staining for CD34, and then the selected regions were revisited at a 
high resolution of magnification. The regions, that included dust and dirt as well as areas of 
artifactual staining on the slides, were excluded. The analysed slides were saved with the 
measured hotspot areas in the high resolution image. The number of vessels was examined at 
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all magnification levels of 4x, 10x, 20x, 40x, 60x and then quantified at 200 magnifications. 
Three to five hot spot fields were counted for vessel density. The examination of each hot spot 
corresponded to a number of vessels confined to an area of 0.74 mm. CD34 histochemical 
positive reaction was counted from intratumoural and peritumoural areas.  
The intratumoural microvessel density (iMVD) was defined as a single endothelial cell or a 
cluster of endothelial cells, set around a visible lumen and clearly separated from adjacent 
connective tissue components within the neoplastic stromal tissue in one high power field 
representing 0.74 mm². The peritumoural microvessel density (pMVD) was defined as a 
stromal tissue space starting from the tumour margin in one high power field representing 
0.74 mm².  
After scanning all of the slide sections, the selected hotspots regions were saved as a tiff 
folder. All information data were then exported to an Excel table within the system.  Blood 
vessel invasion, which was present in CD34 positive vessels occupied by neoplastic cells, was 
also estimated, as well as inflammation.  MVD was counted without any previous knowledge 
of the patients’ outcome or other pertaining data. 
2.3. Statistical analysis 
After showing a normal distribution in a one-sample Kolmogorov-Smirnov test, the 
association between the different histopathological parameters and MVD was performed by 
using a way of variance analysis, the ANOVA system. The relation between the lymph node 
status and the microvessel density was compared using a t-test. Survival curves were traced 
according to Kaplan-Meier, and the differences were analysed using log-rank test (level of 
significance <0.05). High and low MVD were defined above and below the median MVD, 
respectively. 
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3. Results 
 
3.1. Morphological features of vessels according to intra and peritumoural 
compartments 
The intratumoural CD34-stained vessels were highlighted in red colour and noticed to be 
compressed and small in comparison with the peritumoural vessels. Figures 5 and 6. 
 
 
Figure 5: Intratumoural CD34-expressed endothelial cells of blood vessels. The tumour cells 
are pleomorphic and arranged in nests and broad sheets among them compressed vessels. 
 
 
 
Figure 6: Peritumoural areas with CD34-expressed blood vessels showed different lumen 
calibres and with out compression. 
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Figure 7: Non tumoural areas showing the normal vasculature beneath the epidermis.  
 
3.2. MVD in lymph node positive and negative PSCC 
The number of patients with lymph node metastasis is 30 compared to 31 without metastasis. 
61.2% and 38.8% of patients with a low pMVD were having a node positive and negative 
disease respectively. 37.9% and 62.1% of patients with high pMVD were having a node 
positive and negative disease respectively. Figure 8.  
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Figure 8: This figure shows the distribution of the patients according to their lymph node 
status to pMVD. It is noticed that the majority of node positive patients were having low 
pMVD. 
 
No difference was noticed concerning iMVD. 50% of both patients groups with a low iMVD 
were having a node positive and negative disease. 48.3% and 51,7% of patients with high 
iMVD were having a node positive and negative disease respectively. Figure 9.  
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Figure 9: This figure shows the distribution of the patients according to their lymph node 
status to iMVD.   
 
The mean peritumoural MVD/0.74mm²(SD) in specimens of patients with lymph node 
metastasis was 57.30 (±3.93) and 66.59 (±7.45) in those without lymph node metastasis 
respectively (p=0.23). Similarly, the mean intratumoural MVD showed no difference in both 
groups: 38.88 (±3.06) and 44.72 (±5.78), respectively (t-test p=0.331). Figures 10 and 11. 
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Figure 10: Peritumoural MVD in negative and positive lymph node status. 
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Figure 11: Intratumoural MVD in negative and positive lymph node status. 
 
3.3. MVD and its correlation with T Stage 
We found that the mean microvessel density MVD/0.74mm² (SD) in the non tumoural area 
was 28.84 (±2.5) and with the comparison between peritumoural and intratumoural 
microvessel density further difference according to the tumour stages was also found. The 
comparison showed that the mean was pMVD 58.66 (±3.12), and thus significantly higher 
than the iMVD with a mean MVD of 38.76 (±2.41) (ANOVA p= <0.0001).  
The mean pMVD as compared to the T stage was 55.9 (±5.60), 56.8 (±4.00) and 78.86 
(±8.71) in T1, T2 and T3, respectively (ANOVA p= 0.06). The mean iMVD was 32.35 
(±3.16), 37.94 (±3.35) and 62.66 (±5.47) in T1, T2 and T3, respectively (ANOVA p= 0.0006) 
with increasing tendency. The mean MVD was higher in specimens with T3 tumours and 
almost comparable between T1 and T2 intratumoural and peritumoural. There is only one 
patient with stage T4, therefore this patient is not represented in the statistics and figures. 
Figures12 and 13. 
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Figure 12: Peritumoural MVD according to tumour stage. 
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Figure 13: Intratumoural MVD according to tumour stage. 
 
3.4. MVD and its correlation with the tumour grade 
Regarding tumour grading, the numbers of patients with G1, G2, and G3 were 12, 26 and 23 
respectively. The mean peritumoural MVD/0.74 mm² (SD) was 54.3 (±9.60), 57.8 (±4.01) 
and 61.9 (±5.01) in G1, G2 and G3, respectively (ANOVA p= 0.67). The mean intratumoural 
MVD was 41.8 (±7.36), 36.9 (±3.39) and 39.3 (±3.57) in G1, G2 and G3, respectively 
(ANOVA p= 0.75). Figures 14-21. 
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Figure 14: Intratumoural MVD according to tumour grade. 
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Figure 15: Peritumoural MVD according to tumour grade.  
 
 
 
Figure16:  Intratumoural MVD showed the expression of CD34 in well-differentiated 
squamous cell carcinoma (G1), the tumour cells resemble normal squamous epithelium and 
contain varying proportion of large differentiated keratinocyte-like squamous cells and always 
presence of intercellular bridges. Keratin pearls are frequently found with scanty mitosis.  
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Figure 17: Peritumoral MVD showed the expression of CD34 in well-differentiated squamous 
cell carcinoma (G1). 
 
 
Figure18: Intratumoral MVD showed the expression of CD34 in moderately differentiated 
squamous cell carcinoma (G2), the tumor cells exhibit more nuclear pleomorphism and 
increased number of mitosis with less keratinization. 
 
 
Figure19: Peritumoral MVD showed the expression of CD34 in moderately differentiated 
squamous cell carcinoma (G2). 
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Figure 20: Intratumoral MVD in poorly differentiated squamous cell carcinoma (G3), the 
tumour cells are characterized by barely discernible intracellular bridges and loss of 
keratinization with high mitotic rate. 
 
 
 
Figure 21: Peritumoral MVD showed the expression of CD34 in poorly differentiated 
squamous cell carcinoma (G3). 
 
3.5. MVD and its correlation with risk groups 
The EAU guidelines divide the patients into high, intermediate and low risk groups. The 
patients with high grade tumour (G3) or with involvement of the corpora (≥ T2) and those 
with T1 G2 are classified as high and intermediate risk groups, respectively. The rest not 
setting in one of these groups are classified as low risk. The number of patients was 45, 10 
and 6 in the high, intermediate, low risk group, respectively. The mean peritumoural 
MVD/0.74 mm² was 47.1, 61.6, and 59.6 in the low, intermediate, and high risk group 
respectively (ANOVA p= 0.47). The mean intratumoural MVD/0.74 mm² was 33.5, 31.6 and 
41.1 in the low, intermediate, high risk group, respectively (ANOVA p= 0.28). Both 
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peritumoural and intratumoural MVD in this comparison are not statistically significant. 
Figures 22 and 23. 
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Figure 22: Peritumoural MVD according to EAU risk groups.  
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Figure 23: Intratumoural MVD according to EAU risk groups.  
 
3.6. MVD and its correlation with inflammation  
The number of patients with acute inflammatory cells (neutrophiles, basophiles and 
eosinophiles granulocytes) associated with PSCC was 30, compared to 31 with chronic 
inflammatory cells (lymphocytes and plasma cells). The mean peritumoural MVD/0.74 mm² 
was 57.3 in chronic inflammation and 60.1 in acute inflammation (p value test = 0.66). The 
mean intratumoural MVD/0.74 mm² was 37.2 in chronic inflammation and 40.4 in acute 
inflammation (p value test = 0.52). Figures 24-27. 
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Figure 24: Peritumoural MVD in chronic and acute inflammation. 
ch
ro
ni
c
ac
ut
e
0
20
40
60
80
Mean=40.4
Mean=37.2
iM
V
D
 
Figure 25: Intratumoural MVD in chronic and acute inflammation. 
 
 
Figure 26: Acute inflammatory cells at the periphery of tumour cells. 
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Figure 27: Neoplastic cells surrounded by chronic inflammatory cells. 
 
 
3. 7. MVD and its correlation with patient survival 
The overall survival was significantly higher in patients with a high peritumoural MVD (over 
the median) as compared to low MVD. The 5-year overall survival (OAS) was 75% and 30% 
for those with a high and low peritumoural MVD respectively (log-rank p= 0.017). Figure 28. 
No difference was noticed in the tumour with regard to low and high intratumoural MVD. 
The overall survival was 65.03% and 60.56% for those with high and low intratumoural MVD 
respectively (log-rank p= 0.99). Figure 28. 
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Figure 28: Kaplan Meier graphs showing the survival of patients with PSCC at and above the 
median pMVD. Patients with a higher pMVD had better 5-year survival rates of 75% 
compared to 30% for those with a low pMVD (p= 0.017 using log rank test).  
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4. Discussion 
 
4.1. The dilemma in the diagnosis and treatment of occult lymph node metastases 
The most common controversy in the treatment of PSCC focuses on the pathological lymph 
node (pN) status, which is considered a dilemma. The main reason behind this dilemma is the 
unreliability of clinical methods to detect lymph node metastasis at an early stage. With non-
invasive methods occult metastasis cannot be detected, whether by physical examination, 
ultrasonography, CT or MRI. Up to 60% of patients presenting with PSCC have enlarged 
lymph nodes in the groin. In about 50% of them this is caused by metastatic invasion and in 
the other half by inflammatory reactions. In 20% of those patients presenting with no clinical 
signs of nodal metastasis, will develop metastasis later [11,13,43-45]. Therefore the presence, 
the extent and adequate therapy of inguinal lymph node metastases (LNMs) in patients with 
penile carcinoma are all crucial determinants of the survival rate [3]. Patients with penile 
carcinoma benefit from the early removal of occult LNM. However, lymph node dissection as 
a standard procedure in all patients often leads to unnecessary surgery, accompanied by 
increased morbidity rates [46,47]. Up to date there is no non-invasive or minimally invasive 
staging technique that can determine the lymph node status of penile cancer patients with 
100% accuracy. In order to reduce the number of unnecessary lymph node dissections, several 
attempts have been made to predict nodal involvement in the squamous cell carcinoma (SCC) 
of the penis. These attempts involve sentinel lymph node (SLN) biopsy, which involves 
subjecting patients with penile carcinoma to lymphangiography to detect the anatomical 
position of one or more of lymph node metastases. This method remains the best minimally 
invasive staging modality [48,49], however, it is expensive and not available in all urological 
centres. 
 
A predictor for the presence of lymph node metastases may be deduced from tumor 
characteristics other than tumour stage and tumour grade categories. Risk factors of lymph 
node metastases identified from retrospective studies of PSCC include pathological subtype, 
perineural invasion, lymphovascular invasion, tumour depth or thickness, anatomical site, size 
and growth pattern, depth of invasion, positive surgical margins and urethral invasion [50]. 
The most important adverse pathological prognostic factors associated with lymph node 
metastasis appear to be perineural invasion, vascular invasion and a high histological grade 
[12]. Histopathological staging and grading of penile SCC are important in characterizing the 
malignant and metastatic potential of this rare tumour [51]. Therefore, we tried to find a 
 28 
possible mechanism in this study to predict tumour-aggressiveness through the assessment of 
angiogenesis by using microvessel density (MVD) of the primary tumour. According to our 
knowledge, the role of angiogenesis in PSCC has never been discussed and this is the first 
translational study to report a correlation between MVD and the outcome in PSCC using a 
fully automated method for vessel counting with defined inclusion criteria. A commonly used 
surrogate parameter of angiogenesis is the microvessel density, i.e. the number of blood 
vessels counted in a given area of tissue. 
 
4.2. Correlation between microvessel density and survival  
In genitourinary tumours a high MVD was a predictor of poor outcome in certain tumours, 
including carcinoma of the bladder [52], prostate [53], kidney [54] and tumours of the testes 
[55]. However, this is not universally the case and some studies have found no significant 
correlation between MVD and outcome [56,57], while others found that a high MVD 
correlated with a better outcome in carcinoma of the kidney and urinary bladder [58,59]. 
Although most studies have demonstrated that there is an inverse relationship between tumour 
vascularity and patient survival in various types of tumours, there are also conflicting reports 
regarding the relationship between the two. Inconclusive results have been published not only 
on the level of different urological tumours but also on the level of squamous cell carcinoma 
of head and neck, and uterine cervix [60-75]. Thus, until now the correlation between MVD 
and survival in patients with squamous cell carcinoma is also still controversial.  
In our study the numbers of patients with lymph node metastasis were 30 compared to 31 
cases with no metastasis. The mean peritumoural MVD in specimens of patients with lymph 
node metastasis /0.74mm² (SD) was 57.30 (±3.93) and 66.59 (±7.45) in those without lymph 
node metastasis, respectively (t test p= 0.23). Similarly, the mean intratumoural MVD showed 
no difference in both groups 38.88 (±3.06) and 44.72 (±5.78) respectively (t test p= 0.331). 
We found no correlation between lymph node metastasis and MVD neither intratumourally 
nor peritumourally. This may be due the tumour tendency to invade the lymph vessel before 
the blood vessel.  Naumann et al. studied the lymph vessel density (LVD) in the squamous 
cell carcinoma of the penis as a possible mechanism responsible for LNM. The authors 
concluded that increased LVD does not significantly affect the lymphatic spread in penile 
carcinomas and that there is no correlation between LVD in penile SCC and tumour stage, 
differentiation or prognosis of patients [76].  
The overall survival was significantly higher in patients with a high peritumoral MVD (over 
the median) as compared to low MVD. The 5-year overall survival (OAS) was 75% and 30 % 
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for those with a high and low peritumoural MVD, respectively (log rank p= 0.017). This 
result may be related to the unique biological vascularity of the penis, and the tumour itself is 
almost always associated with inflammation. The continuous exposure of tumour to body 
immune system in the form of lymphocytes and plasma cells response could reduce the 
tumour aggressiveness.  No difference was noticed for OAS with regard to low and high 
intratumoural MVD. The overall survival was 65.03% and 60.56% for those with high and 
low intratumoural MVD respectively (log rank p= 0.99). In a study of Ranieri et al. assessed 
MVD using CD34 in head and neck squamous cell carcinoma. These results measured the 
MVD within the tumour, and no data were reported about the peritumoral field. The data 
showed a better survival for patients with high intratumoral MVD [60]. Furthermore, 
Zätterström et al. showed that the degree of vascularisation in cases of a primary squamous 
cell carcinoma of the head and neck was associated with a better survival. The authors 
reported no correlation between MVD and TNM stage, clinical stage, and histological grade 
[61]. Other studies reported a higher MVD to be seen with increasing T and N stages in 
patients with head and neck SCC [62]. On the other hand, Kyzas et al. showed that high MVD 
and VEGF expression were associated with a worse overall survival and high clinical stage in 
specimens with HNSCC as well as no correlation with the lymph node metastasis was noticed 
[63]. Rubio et al. detected in nasopharyngeal carcinoma patients no statistical differences 
between clinicopathological variables and microvessel number. As a result, angiogenesis can 
be seen as an independent prognostic factor beside tumoural type, size and stage, as well as 
beside metastasis, sex and age of patients [64]. Therefore, inconclusive results have been 
published about the role of MVD in head and neck squamous cell carcinoma (HNSSC).  
These inconsistencies are most likely to be explained by the heterogeneity in the populations 
studied, the antibody detection method, quantification methods, and the treatment modalities 
employed.  
In squamous cell carcinoma of uterine cervix, conflicting results have been reported. Randall 
et al. showed in patients with stage IB uterine cervix SCC, that the 5-year survival rate for 
women with high MVD was 90% versus 63% in women with low MVD [65]. Additional 
study has supported these findings [66]; however, high MVD has also been shown to be 
associated with improved survival [67] or to not correlate with the outcome at all [68]. These 
authors reported the simultaneous quantification and analysis of two separate markers of 
MVD in the same patient cohort. These data showed that CD31 MVD was significantly 
associated with an improvement in both patient free survival and overall survival (OAS) 
independent of prognostic clinical covariates. Triratanachat et al. found MVD was not a poor 
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prognostic parameter in frankly invasive cervical carcinoma, stage >IA [69], which also 
confirms our results. However, Rutgers et al. found no correlation between the main vessel 
count and stage or vessel count and prognosis in stage I-IV carcinoma [68]. They concluded 
that with a power of approximately 70%, the study excludes the hypothesis that an increased 
microvessel density is associated with a worsened prognosis in cervical SSC. Wiggins et al. 
showed that there was no correlation between microvessel count and node status, parametrial 
involvement, depth of invasion, or gross disease. Microvessel count was significantly 
correlated with vascular space involvement [70]. Kainz et al. compared stage IB with stage 
IIB and similarly found no correlation between angiogenesis and tumour stage [71]. Obermair 
et al. reported worse outcome in women with high tumour MVD [72]. Vieiraa et al. found that 
microvessel density was higher in undifferentiated carcinomas. Their study suggested that 
anti-CD34 antibody reactivity in cervical carcinoma was associated with pathoanatomical 
features indicative of poorer prognosis [73].  
 
Discrepancies in the prognostic significance of MVD can be explained, in part, by different 
endothelial markers utilized (CD34, CD31, FVIII,CD105 and CD146). The endothelium of 
tumour and normal tissues is heterogeneous. Thus, pan-endothelial antibodies may not stain 
tumour vessels to the same degree and may generally react better with larger vessels. The 
immunohistochemical detection of tumour-associated microvessels has most commonly been 
performed by using anti von Willbrand Factor (anti-vWF) antibodies directed against the 
endothelial membranes. The antibodies against vWF give good staining of endothelial cells in 
large blood vessels and may provide sufficient information on patient prognosis, however, 
vWF is present in diminished quantities or even absent from some microvessels in normal 
tissues and from many microvessels in tumours. Moreover, vWF is also present on lymphatic 
endothelium. Variability in staining and cross-reactivity with other antigens may produce 
equivocal results. Recent reports have stated that an anti-CD34 antibody gave consistent and 
reproducible staining and did not exhibit the problems inherent to vWF staining [73]. Staining 
for CD34 is both more sensitive and more specific than that for vWF, and is easy to interpret, 
because the anti-CD34 antibody does not have any cross reactivity with stroma. Moreover, the 
microvessel count using CD34 staining was three to four times higher than that using vWF, 
because CD34 identifies the small caliber microvessels associated with neovascularization 
more efficiently than vWF.  Thus, microvessels stained with anti-CD34 antibodies may 
provide more usable and reliable information than those stained for vWF [41].  
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Additional factors that may have impact on the discrepancies in the prognostic significance of 
MVD could be the variability in the choice of hotspots and the method of vessel counting 
(manual vs. automated) as well as the organ involved. Another factor to be considered is the 
tumour neovascularisation, which is a dynamic pathophysiological process. The sequence of 
actions requires quantitative, non-invasive and repeatable assays to estimate the functional 
angiogenic activity of the tumour. 
 
4.3. Morphology of intratumoural and peritumoural microvessel density  
In this study we have found that MVD increased in the peritumoural area more than within 
the tumour itself. These examination results of the intratumoural CD34-stained vessels 
revealed smaller, collapsed or narrower lumen than in the peritumoural present vessels. These 
observations mirror the results of animal studies, which have shown compression of the 
intratumoural vessels than the vessels present peritumoural because of high interstitial 
pressure [74].  
 
4.4. Correlation between microvessel density and risk group of patients with 
histopathologic parameters  
We have found that the mean peritumoural MVD in low, intermediate and high risk groups 
was 47.1, 61.6 and 59.6, respectively (ANOVA p= 0.47). The mean intratumoural MVD in 
low, intermediate and high risk groups was 33.5, 31.6, and 41.1, respectively (ANOVA p= 
0.28). These results showed no statistical significance with respect to the correlation between 
intra- and peritumoural MVD and different patients risk groups. 
We have found intratumoural microvessel density and peritumoural microvessel density 
increased with increasing tumour stages. The mean peritumoural and intratumoural MVD as 
compared to the T stage was with an increasing tendency from T1 to T2 and higher in 
specimens with T3. We could not find a statistically significant relationship between MVD 
and tumour stage. Our results correlate with the results reported by Lopes et al. The authors 
showed that MVD was not influenced by the pathological stage and histological grade of the 
primary tumour [75]. 
Regarding the tumour grade, we have found that the mean peritumoural MVD was 54.3, 57.8 
and 61.9 in G1, G2 and G3, respectively (ANOVA p= 0.67). The mean intratumoural MVD 
was 41.8, 36.9 and 39.3 in G1, G2 and G3, respectively (ANOVA p= 0.75). Maiolino et al. 
[77] evaluated microvessel density in canine cutaneous squamous cell carcinomas. The 
authors noted that MVD progressively increased from more-differentiated (Grade I) to poorly-
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differentiated (Grade IV). Bowden et al. showed VEGF was expressed in cutaneous squamous 
cell carcinoma of the head and neck, and it was significantly associated with the degree of 
tumor differentiation [78]. These results agree with our results. 
We also have found that the mean peritumoural MVD was in chronic inflammation 57.3 and 
in acute inflammation 60.1 (p= 0.66). The mean intratumoural MVD was in chronic 
inflammation 37.2 and in acute inflammation 40.4 (p= 0.52). We have found no statistical 
significance in correlation between peritumoural and intratumoural MVD and inflammation. 
All investigated specimens of PSCC were associated with either acute or chronic 
inflammation. Ono Y. et al. suggested that Tumor-associated tissue eosinophilia improves the 
survival of patients with advanced penile   cancer [79]. In 1979, Mihatsch et al. were the first 
to report a significantly better 1-year survival when lymphocytes, plasma cells and/or lymph 
follicles were present in invasive carcinoma of the bladder [80]. In another study in urothelial 
carcinoma, Offersen et al. [59] showed a survival advantage for patients with intense 
inflammation in their tumours with a correlation to significantly increased vascular density. 
MVD was very closely associated to the degree of inflammation and even represented an 
independent parameter for better survival using overall death as the end-point. The survival 
advantage was described to reflect a host versus tumour response, which could reflect the 
ability of the patient to mount an immune response.  
In our study, all other correlations between MVD and histopathologic parameters, as tumour 
stage, grade and association with acute or chronic inflammation in the tumor itself or tumour 
boundaries, revealed no significant values (p> 0.05).  
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5. Conclusion 
 
Although SCC of the penis is a rare neoplasm in most countries of the western world, the 
main clinical and pathological prognostic status of lymph node is well known. Contemporary 
imaging modalities are unable to detect clinically occult metastasis resulting from penile 
carcinoma. Only invasive procedures are capable of reliably the presence of lymph node 
metastasis, therefore lymphadenectomy plays a paramount role in treating the metastatic 
penile carcinoma. Unfortunately the timing of lymphadenectomy in clinically node-negative 
patients is often a choice between unnecessary and overtreatment. 
Our results show that survival of patients with PSCC was associated with higher peritumoural 
MVD values with a 5-year OAS of 75% vs. 30% with low peritumoural MVD. This result 
may be related to the unique biological vascularity of the penis; moreover, the tumour is 
almost always associated with inflammation, thus the continuous exposure of the tumour to 
increased blood circulation is also associated with host lymphocytes and plasma cell response. 
This may lead to a persistent defence and withstanding of immune system against the tumour 
cells. The fact that there is no significant difference between MVD in metastatic and non-
metastatic PSCC might indicate that not the absolute number of tumour microvessels, but the 
proliferative and neovascularized tumour areas are of particular interest.  
Furthermore, in this work, the pan-endothelial marker CD34 was used to highlight the blood 
vessels. However, this marker is limited by its inability to distinguish between active and 
resting angiogenic vessels. We conclude that MVD is a prognostic factor in patients with 
PSCC, while the use of specific vascular proliferation markers would permit a distinction 
between active and resting endothelial cells. Nevertheless, further studies are required to 
improve the understanding of the metastatic mechanisms of PSCC. 
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